Skip to main content
. 2021 Jul 19;12:645839. doi: 10.3389/fimmu.2021.645839

Figure 6.

Figure 6

Immunotherapeutic responses in high- and low-risk groups with ovarian cancer. (A) Differential expression of 12 immune checkpoints. (B) Immunotherapeutic responses to anti-PD1 and anti-CTLA4 treatments. (C) Correlation between riskscore and immunotherapy response.